Cheung Lily 4

What Happened

• Lily Cheung, Chief Human Resource Officer of Pliant Therapeutics (PLRX), received a derivative equity award covering 300,000 shares on January 22, 2026. The grant is reported at a $0.00 price (no cash changed hands at grant). The filing classifies the transaction as an award/grant (transaction code A).

Key Details

• Transaction date: 2026-01-22; Filing date: 2026-01-26 (filed timely).
• Consideration/price reported: $0.00; Shares acquired: 300,000 (derivative award).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote (vesting): 1/48th of the shares subject to the option vest in substantially equal installments on each monthly anniversary beginning January 1, 2026, subject to continuous service.
• Transaction type: Award/grant of a derivative security (transaction code A).

Context

• This was a grant of a derivative equity award (option-style award per the footnote) rather than an open-market purchase or sale, so there was no immediate transfer of cash or shares to the market.
• Such grants are typically part of executive compensation and vest over time; they do not necessarily signal immediate insider buying or selling activity.